Thomas Sciascia, Chief Scientific Officer of Trevi Therapeutics ($TRVI), made one open market sale of company shares in the last year, totaling $17,365. His most recent TRVI insider sale occurred on March 25, 2025. These transactions rank 11,100th among 11,678 insiders in our database, well below the average sale amount of 8.6 million across 6.4 transactions. Sciascia reported no open market purchases.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 19, 2026 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | A | Stock Option (right to buy) | 85000 | $0.00 | 85,000.0000 | 145,104,986 | 9999.99% | 0.06% |
| May 31, 2025 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | A | Performance Stock Option (right to buy) | 60000 | $0.00 | 92,000.0000 | 101,971,873 | 187.50% | 0.06% |
| March 25, 2025 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | S | Common Stock | 2631 | $6.60 | 221,373.0000 | 101,971,873 | 1.17% | 0.00% |
| March 25, 2025 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | M | Stock Option (right to buy) | 2631 | $0.00 | 0.0000 | 101,971,873 | 100.00% | 0.00% |
| March 25, 2025 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | M | Common Stock | 2631 | $1.43 | 224,004.0000 | 101,971,873 | 1.19% | 0.00% |
| March 10, 2025 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | A | Performance Stock Option (right to buy) | 32000 | $0.00 | 32,000.0000 | 101,971,873 | 9999.99% | 0.03% |
| Feb. 18, 2025 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | A | Stock Option (right to buy) | 116000 | $0.00 | 116,000.0000 | 101,971,873 | 9999.99% | 0.11% |
| Aug. 19, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | S | Common Stock | 16496 | $2.96 | 220,315.0000 | 99,033,373 | 6.97% | 0.02% |
| Aug. 19, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | M | Stock Option (right to buy) | 16496 | $0.00 | 0.0000 | 99,033,373 | 100.00% | 0.02% |
| Aug. 19, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | M | Common Stock | 16496 | $1.43 | 236,811.0000 | 99,033,373 | 7.49% | 0.02% |
| Aug. 14, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | M | Common Stock | 100 | $1.43 | 220,415.0000 | 99,033,373 | 0.05% | 0.00% |
| Aug. 15, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | M | Common Stock | 12745 | $1.43 | 233,060.0000 | 99,033,373 | 5.78% | 0.01% |
| Aug. 15, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | S | Common Stock | 12745 | $2.79 | 220,315.0000 | 99,033,373 | 5.47% | 0.01% |
| Aug. 16, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | M | Common Stock | 18660 | $1.43 | 238,975.0000 | 99,033,373 | 8.47% | 0.02% |
| Aug. 16, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | S | Common Stock | 18660 | $2.76 | 220,315.0000 | 99,033,373 | 7.81% | 0.02% |
| Aug. 14, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | M | Stock Option (right to buy) | 100 | $0.00 | 47,901.0000 | 99,033,373 | 0.21% | 0.00% |
| Aug. 15, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | M | Stock Option (right to buy) | 12745 | $0.00 | 35,156.0000 | 99,033,373 | 26.61% | 0.01% |
| Aug. 16, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | M | Stock Option (right to buy) | 18660 | $0.00 | 16,496.0000 | 99,033,373 | 53.08% | 0.02% |
| Aug. 14, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | S | Common Stock | 100 | $2.75 | 220,315.0000 | 99,033,373 | 0.05% | 0.00% |
| May 29, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | S | Common Stock | 53368 | $2.55 | 214,433.0000 | 99,033,373 | 19.93% | 0.05% |
| May 29, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | M | Stock Option (right to buy) | 59354 | $0.00 | 0.0000 | 99,033,373 | 100.00% | 0.06% |
| May 29, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | M | Common Stock | 59354 | $2.19 | 267,801.0000 | 99,033,373 | 28.47% | 0.06% |
| Feb. 15, 2024 | Trevi Therapeutics, Inc. | $TRVI | SCIASCIA THOMAS | Chief Scientific Officer | A | Stock Option (right to buy) | 150000 | $0.00 | 150,000.0000 | 99,033,373 | 9999.99% | 0.15% |